USMLE Step 2 CK Lecture Notes 2019: Surgery

USMLE Step 2 CK Lecture Notes 2019: Surgery

The only official Kaplan Lecture Notes for USMLE Step 2 CK cover the comprehensive information you need to ace the USMLE Step 2 and match into the residency of your choice. • Up-to-date. Updated annually by Kaplan’s all-star faculty.• Highly illustrated. Includes color images and tables.• Integrated. Packed with bridges between specialities and basic science.• […]

Tiotropium (Spiriva): A Once-Daily Inhaled Anticholinergic Medication for Chronic Obstructive Pulmonary Disease (Pharmacology Notes) (Drug Overview)

Tiotropium (Spiriva): A Once-Daily Inhaled Anticholinergic Medication for Chronic Obstructive Pulmonary Disease (Pharmacology Notes) (Drug Overview)

Tiotropium represents a new generation of inhaled therapy. No other inhaled product has demonstrated effectiveness with once-daily dosing. Treatment has been associated with improved lung function, decrease in the number of exacerbations, increase in the time to first exacerbation, and improved quality of life. Adverse effects appear to be mild in nature, and the only […]

Agents for Treatment of Overactive Bladder: A Therapeutic Class Review (Pharmacology Notes) (Clinical Report)

Agents for Treatment of Overactive Bladder: A Therapeutic Class Review (Pharmacology Notes) (Clinical Report)

Overactive bladder (OAB) is a medical syndrome defined by symptoms of urgency, with or without urge urinary incontinence (any involuntary loss of urine), usually with frequency and nocturia. Although anticholinergic agents have been the first-line treatment for OAB for many years, the efficacious pharmacologic management of this condition has been compromised by concerns regarding tolerability. […]

Doripenem (Doribax): The Newest Addition to the Carbapenems (Pharmacology Notes)

Doripenem (Doribax): The Newest Addition to the Carbapenems (Pharmacology Notes)

Carbapenems are a class of antimicrobials structurally related to penicillin. Doripenem, the newest agent in this class, was recently approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Its spectrum of activity is similar to that of meropenem and imipenem/cilastatin. Some studies indicate that approximately […]

Palonosetron (Aloxi): A Second-Generation 5-H[T.Sub.3] Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting (Pharmacology Notes) (Drug Overview)

Palonosetron (Aloxi): A Second-Generation 5-H[T.Sub.3] Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting (Pharmacology Notes) (Drug Overview)

In July 2003, the Food and Drug Administration approved palonosetron hydrochloride injection for the treatment of chemotherapy-induced nausea and vomiting (CINV). The newest agent in the class of 5-H[T.sub.3] receptor antagonists (5-H[T.sub.3]RAs), palonosetron differs from other agents in its class by its higher receptor-binding affinity and longer half-life. These pharmacological properties have resulted in improved […]

Fluoroquinolone Drug Class Update (Pharmacology Notes)

Fluoroquinolone Drug Class Update (Pharmacology Notes)

The approval of trovafloxacin (Trovan, Pfizer Pharmaceuticals, New York, NY) by the Food and Drug Administration (FDA) in 1998 was met with great excitement by many clinicians based on its utility as monotherapy for numerous indications. In comparison with other available fluoroquinolones, trovafloxacin offered enhanced activity against anaerobic and gram-positive organisms, including Streptococcus pneumonia. In […]